2019
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, Steele CJ, Lambe SM, Badve S, Gökmen-Polar Y, Pathak HB, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi GN, Hayes DF. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. Journal Of Clinical Oncology 2019, 37: 3484-3492. PMID: 31657982, PMCID: PMC7194448, DOI: 10.1200/jco.19.00693.Peer-Reviewed Original ResearchConceptsStromal tumor-infiltrating lymphocytesTriple-negative breast cancerDisease-free survivalOverall survivalImmune response signaturesBreast cancerEarly-stage triple-negative breast cancerThree-year disease-free survivalParaffin-embedded tumor tissueThird of patientsTumor-infiltrating lymphocytesSubgroup of patientsCox regression modelResponse signatureAdjuvant ACAdjuvant doxorubicinSTIL densityT2N0 diseaseAC chemotherapyNodal statusPrognostic roleImproved prognosisPrognostic valueTumor sizePrognostic marker
2016
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab
Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra AS, Tripathy D, Valero V, Hatzis C, Pusztai L, Murthy R. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. Journal Of Clinical Oncology 2016, 34: 3511-3517. PMID: 27298406, PMCID: PMC6075965, DOI: 10.1200/jco.2016.67.3624.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsDisease ProgressionHumansMaytansineMiddle AgedNeoplasm MetastasisReceptor, ErbB-2Response Evaluation Criteria in Solid TumorsRetreatmentRetrospective StudiesTrastuzumabConceptsMetastatic breast cancerHER2-positive metastatic breast cancerTumor response rateT-DM1Prior pertuzumabCancer HospitalBreast cancerMetastatic human epidermal growth factor receptorResponse rateStandard first-line therapyHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2MD Anderson Cancer CenterHuman epidermal growth factor receptorFourth-line treatmentSmilow Cancer HospitalT-DM1 activityFirst-line therapyThird of patientsGrowth factor receptor 2Contemporary patient populationJames Cancer HospitalResults of patientsAdo-trastuzumab emtansineElectronic pharmacy records
2009
From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro Are Coordinately Co-Expressed in Breast Cancer Biopsy Samples from the I-SPY Trial (CALGB 150007/150012, ACRIN 6657).
Wolf D, Das D, Lenburg M, Paquette J, Spellman P, Gray J, Gray J, Pusztai L, Symmans F, Hatzis C, Esserman L, van 't Veer L, I-SPY Investigators .. From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro Are Coordinately Co-Expressed in Breast Cancer Biopsy Samples from the I-SPY Trial (CALGB 150007/150012, ACRIN 6657). Cancer Research 2009, 69: 2042-2042. DOI: 10.1158/0008-5472.sabcs-09-2042.Peer-Reviewed Original ResearchSensitive cell linesCancer cell linesOutcome dataCell linesI-SPY 2 TRIALI-SPY 1 TRIALInitial tumor responseNeo-adjuvant chemotherapyPre-treatment biopsiesThird of patientsBreast cancer biopsy samplesDrug response predictorsBreast cancer therapyBreast cancer cell linesMEK inhibitor sensitivityExpression of genesTumor responseTherapeutic responseResponse predictorsPatientsBiopsy samplesTumor samplesPatient samplesCancer ResDrug sensitivity